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Abstract
Gaucher disease (GD), the most prevalent lysosome storage disorder,
presents an autosomal recessive mode of inheritance. It is a paradigm for
therapeutic intervention in medical genetics due to the existence of
effective enzyme replacement therapy. We report here the analysis of
GD in 262 unrelated Brazilian patients, carried out in order to establish
the frequency of the most common mutations and to provide prognostic
information based on genotype-phenotype correlations. Among 247
type 1 GD patients, mutation N370S was detected in 47% of all the
alleles, but N370S/N370S homozygosity was found in only 10% of the
patients, a much lower frequency than expected, suggesting that most
individuals presenting this genotype may not receive medical attention.
Recombinant alleles were detected at a high frequency: 44% of the
chromosomes bearing mutation L444P had other mutations derived
from the pseudogene sequence, present in 25% of patients. Three
neuronopathic type 2 patients were homozygous for L444P, all present-
ing additional mutations (E326K or recombinant alleles) that probably
lead to the more severe phenotypes. Six children, classified as type 1 GD
patients, had a L444P/L444P genotype, showing that neuronopathic
symptoms may only manifest later in life. This would indicate the need
for a higher treatment dose during enzyme replacement therapy. Finally,
mutation G377S was present in 4 homozygous type 1 patients and also
in compound heterozygosity in 5 (42%) type 3 patients. These findings
indicate that G377S cannot be unambiguously classified as mild and
suggest an allele-dose effect for this mutation.
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Introduction
Gaucher disease (GD), the most preva-
lent lysosome storage disorder, presents an
autosomal recessive mode of inheritance.
Clinically, it is a multisystemic disease with
variable expression, generally characterized
by hepatosplenomegaly, anemia and throm-
bocytopenia. Bone and pulmonary disease
may also be present. The presence and sever-
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ity of neurologic symptoms define the three
types of GD. Approximately 95% of patients
present type 1 GD (MIM# 230800), without
neurologic involvement and with onset dur-
ing childhood or adulthood (1). Neurono-
pathic variants are type 2 GD (MIM#
230900), characterized by early onset and
survival of up to 2 years of age, and type 3
GD (MIM# 231000) of infantile or juvenile
onset and with a less ominous course with
survival into adulthood.
GD is caused by mutations in the GBA
gene (1q21). This is a 7-kb gene containing
11 exons, which codes for the acid ß-glu-
cosidase enzyme, also known as glucocer-
ebrosidase (2). The absence of this enzyme
leads to the accumulation of glucocerebroside
in the cells of the reticuloendothelial system
and ultimately to the clinical manifestation
of GD. More than 200 GD-causing muta-
tions have been identified so far and the
most frequent ones are [c.1226A>G;N370S]
and [c.1448T>C;L444P], herein called
N370S and L444P, respectively. The clini-
cal diagnosis of GD may be confirmed by
the biochemical assay of acid ß-glucosidase
activity. Unlike enzymatic diagnosis, muta-
tion analysis has a considerable, although
not absolute, predictive value with respect to
disease prognosis (1). Opportunely, an ex-
tensive genotype-phenotype correlation is
present for the most frequent mutations.
Generally, GD-causing mutations are classi-
fied as mild, severe or null alleles (3). The
presence of a mild mutation leads to type 1
GD even in combination with a second se-
vere mutation or a null allele. The neurono-
pathic variants are due to homozygosity of
severe mutations, or the combination of a
severe mutation and a null allele. Homozy-
gosity of null alleles is not found, suggesting
that this genotype is incompatible with life.
Despite the genotype-phenotype correlation,
a variable expression of clinical symptoms
is present in patients with the same geno-
type, indicating the existence of other fac-
tors, genetic and/or environmental, influ-
encing the phenotype (4).
GD is the first lysosome storage disease
for which an efficient enzyme replacement
therapy (ERT) was developed (Imiglucerase)
and became a paradigm for therapeutic in-
tervention in human genetics (5). ERT is the
standard treatment for type 1 and 3 GD
patients, and efficiently ameliorates non-neu-
rological symptoms. The enzyme dose in-
fused during ERT is established for each
patient according to body weight and clini-
cal manifestations. Dose individualization is
subject to medical decision including the
initial dose and its reduction during the life-
long treatment. The high cost of treatment
dictates that ERT should be administered at
the most efficient possible dose. In Brazil,
the patients’ therapy is subsidized by the
public health system. Thus, the disease may
be of low incidence but has a significant
economic impact. There are no estimates of
GD prevalence in Brazil, but there are ap-
proximately 400 diagnosed cases (6), the
third largest patient population undergoing
ERT in the world.
In this study the frequency of the most
common mutations in a sample of 262 unre-
lated Brazilian GD patients was determined.
Several genotype-phenotype correlations
were identified and their implications for the
diagnosis and treatment of GD are discussed.
Patients and Methods
Gaucher disease patients and relatives
Overall, 580 samples were received in
the laboratory, from patients, relatives and
cases with an unconfirmed clinical diagno-
sis of GD. Samples came from the different
regions of Brazil during a three-year period
(2000-2003). The patients with confirmed
GD were diagnosed by their doctors after
medical evaluation and the determination of
reduced glucocerebrosidase activity meas-
ured in leukocytes (6). Only three patients
were Ashkenazi Jewish. Mouth mucus was
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collected by physicians or health profes-
sionals participating in the treatment of the
patients and sent to the laboratory in 2-mL
Eppendorf tubes. Participants signed in-
formed consent forms and the project was
approved by the Brazilian National Com-
mittee of Ethics in Research (CONEP).
Mutation screening, for statistical pur-
poses was performed in one case from each
family, for a total of 262 cases, 247 of which
were classified by their physicians as type 1,
3 as type 2, and 12 as type 3 GD patients.
Since not all of these patients were evaluated
by one of the authors, we could not confirm
the classification in every case. Most of
these patients are undergoing ERT, except
type 2 cases, which are not treated and have
a reduced life expectancy. The genotype
was analyzed separately for type 2 and 3
patients in order to avoid bias in the evalua-
tion of allelic and genotypic frequencies.
Molecular diagnosis
DNA was extracted from mouth mucus
by the method of Richards et al. (7). Muta-
tions N370S, L444P, G377S, c.84insG
(84insG), IVS2+1G>A, c.1263_1317del
(55del), V460V, D409H, and E326K were
analyzed on the basis of restriction fragment
length polymorphism. The enzymatic effect
of these mutations, their screening strategy,
the primers (Invitrogen, Carlsbad, CA, USA),
and restriction endonucleases (New Eng-
land Biolabs, Ipswich, MA, USA or from
Fermentas, Vilnius, Lithuania) used for de-
tection and the reference method, when pre-
viously established, are described in Table
1. After endonuclease digestion, fragments
were submitted to 12% polyacrylamide gel
electrophoresis (mutations N370S, G377S,
84insG, and IVS2+1G>A) or 2% agarose gel
electrophoresis (mutations L444P, V460V,
D409H, 55del, and E326K).
All patients were screened for mutations
N370S and L444P, the most frequent muta-
tions worldwide. Mutation G377S is the third
most frequent mutation in Portugal and was
therefore also included in the initial analy-
sis. In the absence of these three mutations in
one of the alleles, the first one hundred
patients were screened for mutations 84insG
and IVS2+1G>A. Patients homozygous for
N370S, G377S or L444P were investigated
for the presence of mutation 55del, present
in the pseudogene (psGBA) contiguous to
the GBA gene. This deletion, if present in
GBA, would be localized at the annealing
site of primers used for detecting mutations
N370S, G377S and L444P (8).
Because mutation L444P may be a part
of a recombinant allele (REC), with DNA
sequence derived from the highly homolo-
gous psGBA, all patients presenting this
mutation were tested for V460V (9). When
V460V was detected, indicating the pres-
ence of a REC, mutations 55del and D409H
were screened in order to determine the ex-
tent of the recombination sequence. More-
over, when a REC was detected, the patient’s
parents were tested, when possible, to deter-
mine if the mutations were in the same al-
lele. The most frequent RECs are RecNciI
(L444P, A456P and V460V) and RecTL
(D409H, L444P, A456P, and V460V). Due
to the absence of analysis of A456P, we
opted to present RECs by the mutations
actually detected. Finally, the 15 patients
classified as types 2 and 3 were also tested
for 55del, D409H and E326K due to the high
frequency of these mutations among them.
Results
The sample analyzed was composed of
247 (94%) type 1, 3 (1%) type 2 and 12 (5%)
type 3 GD patients. Type 2 GD patients may
be under-represented since they are not
treated by ERT and have a short life expect-
ancy. Nevertheless, the distribution was simi-
lar to that of other studies in distinct popula-
tions (1).
The genotypic distribution in the 247
type 1 patients is shown in Table 2. Among
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the first one hundred patients analyzed, only
one allele harboring mutation 84insG and
none with IVS2+1G>A were detected. There-
after, screening for these mutations was
halted and they were considered to be un-
identified. Almost half of the patients were
compound heterozygotes presenting the
N370S/L444P genotype. Combination of
N370S with a second unidentified mutation
was the second most frequent genotype, pres-
ent in approximately 30% of the alleles. The
remaining patients had many other geno-
types.
Molecular analysis of 6 children with a
clinical diagnosis of type 1 GD showed a
genotype characteristic of type 3 GD (ho-
mozygous for L444P). For statistical pur-
poses these children were considered to be
type 1 patients according to their clinical
characterization, although their genotypes
suggest that neuronopathic symptoms may
be expected to occur later in life.
The mutation frequencies, independent-
ly of their genotypic distribution, are pre-
sented as the first column of Table 3. While
almost half of the patients’ alleles carry
N370S (47%), the other half is divided be-
tween L444P (27%), G377S (2%) and an
Table 1. Screening target, primers and restriction enzymes used for the detection of some mutations that cause
Gaucher disease.
Mutation Phenotypic Screening F and R primers (Ref.) Restriction
(cDNA sequence) effecta target endonuclease
N370S (c.1226A>G) Mild All patients F: 5’gcctttgtccttaccctcg3' XhoI
R: 5’acgaaagttacgcacccaatt3' (32)
G377S (c.1246G>A) Mild/severe All patients F: 5’gcctttgtccttaccctcg3' AluI or PvuII
R: 5’acgaaagttacgcacccaatt3'
L444P (c.1448T>C) Severe All patients F: 5’ctgaaccccgaaggaggac3' Nci I
R: 5’tgaatggagtagccaggtga3' (33)
V460V (c.1497G>C) b Patients with L444P F: 5’ctgaaccccgaaggaggac3' Bcg I
R: 5’tgaatggagtagccaggtga3'
84insG (c.84insG) Null allele First 100 patients F: 5’cactgcctgaagtagatgc3' BsaBI
R: 5’gaatgtcccaagcctttga3'
IVS2+1G>A Null allele First 100 patients F: 5’gaatgtcccaagcctttga3' Hph I
R: 5’aacagagtaagactctggttc3'
D409H (c.1342G>C) Severe Types 2 and 3 F: 5’aaccatgattccctatcttc3' Sty I
Patients with V460V R: 5’gctccctcgtggtgtagagt3'
E326K (c.1093G>A) c Types 2 and 3 First PCR: Bbs I or Bpi I
F: 5’acaaattagctgggtgtggc3'
R: 5’taagctcacactggccctgc3'
Nested PCR:
F: 5’tgtgcaaggtccaggatcag3'
R: 5’gaggtctgctttgcaggaag3'
55del Null allele Types 2 and 3 F: 5’aaccatgattccctatcttc3' d
(c.1263_1317del) R: 5’gctccctcgtggtgtagagt3' (8)
Homozygotes for
N370S, G377S
and L444P
Patients with V460V
aPhenotypic effect of mutations according to Ref. 3. Mutation G377S has been detected with both mild and
severe effects (see text). bMutation V460V is a silent alteration used to indicate the presence of a recombinant
allele. cE326K is a modifier that may be present in combination with other Gaucher disease-causing mutations.
dIdentification of mutation 55del may be visualized directly after PCR.
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unidentified mutation (24%).
Since mutation L444P may be present
alone or as part of a REC, this possibility was
always examined. Among type 1 GD pa-
tients, 46% (62/134) of alleles with L444P
were found to be RECs with L444P+V460V.
Testing for D409H followed the detection of
V460V and only 2% (3/134) of alleles with
L444P were positive, disclosing a REC with
L444P+V460V+D409H. Mutation 55del was
not detected in any of the RECs, suggesting
that they probably had pseudogene-derived
mutations restricted to exons 9 and 10. How-
ever, other recombination events upstream
from 55del may be present. When including
type 2 and 3 patients in the statistical analy-
sis, RECs were identified in 44% (66/150) of
the chromosomes bearing mutation L444P
and in 25% (66/262) of all GD patients.
The 15 patients with type 2 and 3 GD
were screened for mutations N370S, G377S,
L444P, V460V, 55del, D409H, and E326K.
Table 4 presents the genotypes found. We
detected a homozygote patient whose par-
ents are first cousins presenting E326K in
combination with L444P in both alleles with
a type 2 clinical phenotype. The only com-
pound heterozygote presenting L444P in
combination with a REC also had type 2 GD.
Among the type 3 patients, the presence of
mutations N370S in one case and G377S in
5 cases was unexpected since these are gen-
erally considered to be mild mutations (3).
Table 3. Frequency of the most common mutations in Brazilian, Portuguese and non-Jewish North American
type 1 Gaucher disease patients.
Mutation Brazil United States of America Portugal
Present study Zhao and Grabowski, 2002 (12) Amaral et al., 1996 (13)
N (%) N (%) N (%)
N370S 232 (47.0%) 183 (43.7%) 29 (53.7%)
L444P 134 (27.1%) 107 (25.5%) 7 (13.0%)
G377S 11 (2.2%) Not determined 4 (7.4%)
Others 117 (23.7%) 129 (30.8%) 14 (25.9%)
Total 494 alleles (100%) 419 alleles (100%) 54 alleles (100%)
Statistical analysis comparing the present study with the North American sample considered G377S to belong
to the “others” category.
Discussion
Frequency of the most common mutations
Although 47% of all GD-causing mu-
tations are N370S (Table 3), only ~10% of
the patients are N370S/N370S homozy-
gotes (Table 2), a frequency much lower
than the 22% expected (0.472). These data
probably reflect the fact that many N370S
homozygotes are not obtaining medical
attention due to the absence or mildness of
symptoms. The 24 homozygotes herein
detected indicate a penetrance of 45% for
this genotype (0.10/0.22), a value that is
close to that described for the Ashkenazi
Jewish population (10) and for the Portu-
guese population (11). These cases indi-
Table 2. Genotypic frequency observed in 247
Brazilian patients with type 1 Gaucher disease.
Genotype Number of patients (frequency)
N370S/L444P 112 (45.3%)
N370S/? 70 (28.3%)
N370S/N370S 24 (9.7%)
         ?/? 19 (7.7%)
L444P/? 9 (3.6%)
L444P/L444P 6 (2.4%)
G377S/G377S 4 (1.6%)
G377S/N370S 2 (0.8%)
G377S/L444P 1 (0.4%)
Total 247 (100%)
? = unidentified mutation.
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cate that despite its Mendelian mode of in-
heritance, GD presents complex phenotypes.
The frequency of the two most common
GD-causing mutations among Brazilian pa-
tients is similar to that described for other
populations, where N370S and L444P rep-
resent roughly half and one quarter of the
alleles, respectively (1). Mutations 84insG
and IVS2+1G>A were found to be too rare.
In fact, these mutations have a high fre-
quency among Jewish patients but not in the
general population of most countries (1).
The low detection rate of the 84insG and
IVS2+1G>A in the present study may re-
flect the low frequency of the Jewish popu-
lation (<0.1%) in Brazil.
From Table 3 it is possible to observe
that the frequency of the most common mu-
tations in Brazilian type 1 GD patients de-
tected in the present study is similar to that
found in a sample of non-Jewish North Am-
ericans (12) (P = 0.263). However, it is
significantly different (P = 0.028) when com-
pared to that of Portuguese cases (13), ac-
cording to chi-square analysis. The genetic
background of the Brazilian population in-
cludes important African and Indigenous
components, in addition to the Portuguese
ancestry, that may explain the greater simi-
larity to the North American sample.
Mutation G377S is the third most frequent
among GD patients in Portugal and Spain
(13). In Brazil, it also appeared at a consider-
able frequency (2.2%), indicating that it is
important in preliminary screening. A corre-
spondence in mutations causing another lyso-
some storage disease has also been described
for Tay-Sachs disease and points to a common
origin of the mutated alleles prior to the Portu-
guese colonization of Brazil (14).
Among the alleles with L444P, 44% (66/
150) were shown to be RECs, present in 25.2%
(66/262) of patients, corresponding to 12.6%
(66/524) of the alleles studied. Our approach
was limited by the lack of analysis of the
A456P mutation, present in the RECs. There-
fore, we have opted to present RECs by the
mutations actually diagnosed. Since some pa-
tients may have A456P and lack the silent
mutation in V460V, the frequency of RECs in
this sample may be even higher. The high
frequency of RECs was also described in other
countries (9,15). It is generally observed that
the RECs have a more severe impact on clini-
cal manifestation than L444P alone (9,16-18).
In agreement with this observation the three
homozygotes for L444P additionally carrying
E326K or RECs had type 2 GD, while those
with genotype L444P/L444P but lacking com-
plex alleles had milder phenotypes. It is pos-
sible that these patients’ more severe pheno-
types reflect a modifier effect of E326K and
RECs leading to a lower residual enzyme
activity, although other loci may also have
influenced the severity of the phenotype (4,19).
The type 2 patient with the L444P+E326K/
L444P+E326K genotype did not present the
severe perinatal-lethal phenotype, downplay-
ing this genotype-phenotype correlation (20).
Table 4. Genotypes of 15 neuronopathic Brazilian
patients with Gaucher disease.
Genotype Phenotype
L444P+E326K/L444P+E326Ka,b Type 2
L444P+V460V/L444P Type 2
L444P+E326K/L444Pb Type 2
L444P/L444P Type 3
L444P/D409H Type 3
L444P/D409H Type 3
L444P+V460V/? Type 3
L444P+V460V/? Type 3
55del/? Type 3
L444P+E326K/G377S Type 3d/ME
L444P+E326K/G377Sb Type 3d
L444P/G377S/E326Kc Type 3d
G377S/? Type 3d
G377S/? Type 3d
L444P+V460V/N370S Type 3d/ME
ME = myoclonic epilepsy. aParents are first cous-
ins. bThese patients have siblings not included in
this study, presenting the same genotype and
phenotype. cE326K phase was not determined,
i.e., it was cis or trans to L444P. dNeuronopathic
patients with a clinical diagnosis of type 3 but
carrying mutations considered to be mild. The
patient carrying N370S did not have a detailed
oculomotor evaluation.
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Type 1 pre-neuronopathic affected children
Among type 3 GD patients, neurological
manifestations appear after 10 years of age in
50% of the cases (1). Therefore, it is always
possible that children under this age, diag-
nosed as type 1, may actually be type 3 pa-
tients that are in a pre-neuronopathic phase.
Molecular diagnosis may help to identify these
patients and this was the case for 6 children in
this study, aged 5 to 6 years, in which mutation
L444P was detected in homozygosity. It is
possible that other children clinically classi-
fied as type 1 patients, with unidentified muta-
tions and without a mild mutation, are in the
same situation. Although only ~5% of GD
patients are type 3 cases, the onset of GD is
generally during infancy, which makes the
possibility of a pre-neuronopathic patient a
frequent doubt. The anticipation of the diag-
nosis of a neuronopathic GD variant by DNA
testing is due to the need to inform the family,
since these patients are likely to manifest de-
velopmental and language problems (4,21).
More important is the impact on ERT. One
possibility is that a high-dose treatment may
impact the neuronopathic symptoms (21,22)
but conclusive evidence is still lacking for
GD. The European consensus for the treat-
ment of neuronopathic GD has established
that the ERT of type 3 patients, including the
pre-neuronopathic ones identified by molecu-
lar diagnosis, is to be performed at a higher
dose that should not be reduced even after
symptoms ameliorate (23).
Neuronopathic patients with mutations
N370S and G377S
The evidence for considering G377S a
mild mutation is based on its high residual
enzyme activity (17.6%) according to meas-
urement of acid ß-glucosidase activity (24).
Moreover, all reports of G377S homozy-
gotes involve type 1 GD patients (16,25-27).
Accordingly, in the present study four G377S
homozygotes had a type 1 phenotype. How-
ever, five compound heterozygotes carrying
one G377S allele were type 3 patients. Other
reports have also detected type 3 patients
carrying one copy of G377S (3,28-30). These
observations suggest the possibility of an
allele-dose effect, whereby two copies of
G377S would lead to an enzymatic residual
activity sufficient to prevent neurological
involvement, but one copy of G377S with a
second severe mutation would lead to type 3
GD. An allele dose-effect has already been
described for mutation K79N (31). In this
model, the residual activity of mutant en-
zymes produced by the two alleles should be
considered in an additive manner. Some
mutations, such as G377S, K79N, N188S,
V394L, and R463C could be at the limit of
residual activity that elicits neuropathic
symptoms (3,16,31).
The patients reported here represent fur-
ther in vivo evidence for a critical role of a
GD-causing mutation in the development of
neurological disease. However, the partici-
pation of other modifiers cannot be excluded.
In this study, another Brazilian family with
two siblings (aged 5 and 15 years) present-
ing the G377S/L444P genotype lacked any
neurological involvement (Table 2). These
siblings were shown not to carry the E326K
mutation (data not shown), while 2 other
patients with genotype G377S/L444P+
E326K presented neuronopathic symptoms
(Table 4). This finding reinforces a possible
negative modifier effect of E326K.
The last case in Table 4 presents neu-
ronopathic symptoms that appeared to be
inconsistent with his genotype (N370S/
L444P+V460V). Mutation N370S is in trans
to the REC allele that was inherited from the
mother. The mild effect of N370S has been
well described in hundreds of type 1 GD
patients reported so far and contrasts to the
neuronopathic phenotype in this case. How-
ever, the patient herein described may suffer
from hypoxic-ischemic encephalopathy and
therefore her neuronopathic manifestation
may not be a consequence of GD.
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It is clear that DNA testing provides in-
formation both on the diagnosis and the
prognosis of GD and new insights on geno-
type-phenotype correlations should be
promptly integrated into medical practice.
Moreover, since ERT is individualized and
the treatment dose is subject to medical deci-
sion, molecular diagnosis may be critical to
establish a proper dose, as in the case of the
L444P homozygote children still lacking
neurological symptoms. Finally, our find-
ings indicate that an allele dose-effect may
be associated with mutation G377S. This
mutation should be part of the screening
panel for GD patients from Iberian coun-
tries, including their former colonies. Fur-
ther studies may be critical to establish its
exact genotype-phenotype correlation.
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The David Rockefeller Center for Latin American Stud-
ies, Harvard University, invites candidates for its “Visit-
ing Scholars and Fellows Program”. The “Visiting Schol-
ars and Fellows Program” is a program for academic and
non-academic professionals interested in developing re-
search for a determined period of time (one or two aca-
demic semesters) while residing at Harvard University.
The selection of professionals is made by an examination.
With the support of Mr. Jorge Paulo Lemann, the Center
recently created the “Lemann Visiting Fellowship”. This
is a fellowship for a professional for the above mentioned
program whose research project has Brazil as the study
objective. This fellowship is awarded once each academic
year (September-June) and covers the administrative ex-
penses of the Center and airline tickets. The professional
will also receive financial assistance of US$15,000 (fif-
teen thousand American dollars, subject to income tax),
regardless of the number of semesters for which he is
accepted.
Candidates must include, in English:
- Curriculum vitae;
- One page explaining why the candidate
wishes to study at Harvard;
- Three or four pages describing the proposed
research project;
- Two letters of reference from persons who can prove
the qualifications of the candidate and the importance
of the proposed project.
For additional information, contact:
Visiting Scholars and Fellows Program Coordinator
David Rockefeller Center for Latin American Studies
Harvard University
61 Kirkland Street
Cambridge, MA 02138 USA
Tel: (617) 495-3366  Fax: (617) 496-2802
e-mail: drclas@fas.harvard.edu
Web site: http://www.fas.harvard.edu/~drclas
David Rockefeller Center for
Latin American Studies
Harvard University
“Lemann Visiting Scholars and Fellows
Program“ Brasil
The Alexander Von Humboldt Foundation, which exists
more than 130 years and whose actual structure was estab-
lished a few years after WWII (1953), is offering fellow-
ships for post-doctorate study and for specialized research
projects in all areas of knowledge. There are 500 fellow-
ships annually, distributed without limitation of national-
ity, and 150 fellowships (Feodor Lynen Research Fellow-
ships), only for German researchers and professors, to
work as invited researchers of ex-fellows of all nationali-
ties and their Universities. The Alexander Von Humboldt
Foundation Fellowships are open to all professors who
meet the above-mentioned requisites and who are less
than 40 years of age. There is also one specialized fellow-
ship for candidates between 40 and 45 years of age. These
fellowships are for 6 to 24 months, receiving 3400 to 4200
German marks monthly.
Interested candidates should contact:
Alexander Von Humboldt-Stiftung
Jean Paul Strasse 12
D-53173 BONN (Germany)
Telefax: 0049-228-833-199
Internet: http://www.avh.de
Ex-fellows of the Foundation are represented
in Brazil by:
“Clube Humboldt do Brasil”
Av. Brig. Faria Lima, 1572 - 7o andar, sala 705
01463-900 São Paulo, SP
President Prof. Dr. Bruno Konig Junior
Department of Anatomy,  ICB, USP, São Paulo, Brasil
Tel: (011)818-7258
Post-doctorate fellowship in
Germany Alexander Von
Humboldt Foundation
